{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:34:52Z","timestamp":1787315692579,"version":"build-2736575974"},"reference-count":205,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The human immune system consists of two main components: innate and adaptive immunity. To date, research on the pathogenesis of autoimmune neurological diseases has primarily focused on the role of adaptive immunity. However, growing evidence highlights the significant contribution of innate immune mechanisms in the development of neurological disorders. The aim of this article is to present the current state of knowledge regarding the involvement of innate immunity in the pathogenesis and treatment of selected autoimmune neurological diseases: multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), MOG antibody-associated disease (MOGAD), myasthenia gravis (MG), and chronic inflammatory demyelinating polyneuropathy (CIDP). A literature review was conducted, including both experimental and clinical data on the activity of innate immune effector cells\u2014such as dendritic cells, macrophages, microglia, and natural killer (NK) cells\u2014as well as plasma proteins, including the complement system. Relevant clinical and preclinical studies on targeted therapies affecting these components were also identified. All analyzed diseases demonstrate the involvement of innate immune elements in the initiation and maintenance of the inflammatory process. Furthermore, it has been shown that therapies targeting these components may offer clinical benefits.<\/jats:p>","DOI":"10.3390\/jcm14207235","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:57:42Z","timestamp":1760529462000},"page":"7235","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Innate Immunity in the Pathogenesis of Selected Autoimmune Neurological Diseases"],"prefix":"10.3390","volume":"14","author":[{"given":"Julia","family":"Rudnicka-Czerwiec","sequence":"first","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Rzesz\u00f3w, al. Tadeusza Rejtana 16C, 35-959 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2860-6456","authenticated-orcid":false,"given":"Halina","family":"Bartosik-Psujek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Rzesz\u00f3w, al. Tadeusza Rejtana 16C, 35-959 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S442","DOI":"10.1067\/mai.2003.125","article-title":"Overview of the immune response","volume":"111","author":"Chaplin","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jaci.2010.01.058","article-title":"Identification and functions of pattern-recognition receptors","volume":"125","author":"Kumagai","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2008-07-019307","article-title":"TLRs and innate immunity","volume":"113","author":"Beutler","year":"2009","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"32 e8","DOI":"10.1111\/j.1365-3164.2012.01082.x","article-title":"Innate immune defense system of the skin","volume":"24","author":"Afshar","year":"2013","journal-title":"Vet. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/cei.13279","article-title":"Neuroimmunology\u2014The past, present and future","volume":"197","author":"Nutma","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"Kobelt","year":"2017","journal-title":"Mult. Scler."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jneuroim.2009.10.015","article-title":"Role of the innate immune system in the pathogenesis of multiple sclerosis","volume":"221","author":"Gandhi","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1474-4422(14)70305-9","article-title":"Role of the innate and adaptive immune responses in the course of multiple sclerosis","volume":"14","author":"Hemmer","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer, S., Hellenthal, G., Pirinen, M., Spencer, C.C., Patsopoulos, N.A., Moutsianas, L., Dilthey, A., and Su, Z. (2011). Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 476, 214\u2013219.","DOI":"10.1038\/nature10251"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.20091844","article-title":"GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization","volume":"207","author":"King","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/ni.3703","article-title":"Ontogeny and homeostasis of CNS myeloid cells","volume":"18","author":"Prinz","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/brain\/awq081","article-title":"Induction of inhibitory central nervous system-derived and stimulatory blood-derived dendritic cells suggests a dual role for granulocyte\u2013macrophage colony-stimulating factor in central nervous system inflammation","volume":"133","author":"Hesske","year":"2010","journal-title":"Brain"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nm1202","article-title":"Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis","volume":"11","author":"McMahon","year":"2005","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jaci.2012.06.022","article-title":"Crosstalk of regulatory T cells and tolerogenic dendritic cells prevents contact allergy in subjects with low zone tolerance","volume":"130","author":"Luckey","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1084\/jem.192.9.1213","article-title":"Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells","volume":"192","author":"Jonuleit","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Piacente, F., Bottero, M., Benzi, A., Vigo, T., Uccelli, A., Bruzzone, S., and Ferrara, G. (2022). Neuroprotective potential of dendritic cells and sirtuins in multiple sclerosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084352"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ana.21800","article-title":"Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions","volume":"66","author":"Henderson","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0171-2985(96)80024-6","article-title":"Macrophages in multiple sclerosis","volume":"195","author":"Sommermeier","year":"1996","journal-title":"Immunobiology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0165-5728(86)90005-6","article-title":"Immunohistological analysis of macrophages in the central nervous system of Lewis rats with acute experimental allergic encephalomyelitis","volume":"11","author":"Polman","year":"1986","journal-title":"J. Neuroimmunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.4049\/jimmunol.126.2.614","article-title":"The effects of macrophage depletion on the clinical and pathologic expression of experimental allergic encephalomyelitis","volume":"126","author":"Brosnan","year":"1981","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jneuroim.2015.11.004","article-title":"Therapeutic depletion of monocyte-derived cells protects from long-term axonal loss in experimental autoimmune encephalomyelitis","volume":"290","author":"Moreno","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/nn.2887","article-title":"Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool","volume":"14","author":"Ajami","year":"2011","journal-title":"Nat. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","article-title":"The chemokine system in diverse forms of macrophage activation and polarization","volume":"25","author":"Mantovani","year":"2004","journal-title":"Trends Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1182\/blood-2008-07-168575","article-title":"Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease","volume":"113","author":"King","year":"2009","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.immuni.2015.08.010","article-title":"The cytokine GM-CSF drives the inflammatory signature of CCR2+ monocytes and licenses autoimmunity","volume":"43","author":"Croxford","year":"2015","journal-title":"Immunity"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.imlet.2014.03.006","article-title":"Macrophages: A double-edged sword in experimental autoimmune encephalomyelitis","volume":"160","author":"Jiang","year":"2014","journal-title":"Immunol. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/icb.2008.99","article-title":"Type II-activated macrophages suppress the development of experimental autoimmune encephalomyelitis","volume":"87","author":"Tierney","year":"2009","journal-title":"Immunol. Cell Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/eji.201141947","article-title":"IL-33 attenuates EAE by suppressing IL-17 and IFN-\u03b3 production and inducing alternatively activated macrophages","volume":"42","author":"Jiang","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: Pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nm1177","article-title":"Experimental autoimmune encephalomyelitis repressed by microglial paralysis","volume":"11","author":"Heppner","year":"2005","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/brain\/awx113","article-title":"Loss of \u2018homeostatic\u2019 microglia and patterns of their activation in active multiple sclerosis","volume":"140","author":"Zrzavy","year":"2017","journal-title":"Brain"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00401-014-1310-2","article-title":"Macrophage subsets and microglia in multiple sclerosis","volume":"128","author":"Bogie","year":"2014","journal-title":"Acta Neuropathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jneuroim.2004.08.011","article-title":"Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination","volume":"158","author":"Li","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.conb.2017.10.001","article-title":"Microglia: Origins, homeostasis, and roles in myelin repair","volume":"47","author":"Lloyd","year":"2017","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/nn.3469","article-title":"M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination","volume":"16","author":"Miron","year":"2013","journal-title":"Nat. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/s41467-019-08976-7","article-title":"Transcriptional profiling of human microglia reveals grey-white matter heterogeneity and multiple sclerosis-associated changes","volume":"10","author":"Ulas","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nn.4222","article-title":"Microglial brain region-dependent diversity and selective regional sensitivities to aging","volume":"19","author":"Grabert","year":"2016","journal-title":"Nat. Neurosci."},{"key":"ref_39","first-page":"251","article-title":"Experimental autoimmune encephalomyelitis in mice lacking glial fibrillary acidic protein is characterized by a more severe clinical course and an infiltrative central nervous system lesion","volume":"152","author":"Liedtke","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/glia.21088","article-title":"Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease","volume":"59","author":"Owens","year":"2011","journal-title":"Glia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm.3681","article-title":"Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation","volume":"20","author":"Mayo","year":"2014","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2020.08.012","article-title":"Astrocyte crosstalk in CNS inflammation","volume":"108","author":"Linnerbauer","year":"2020","journal-title":"Neuron"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00281-015-0515-3","article-title":"Control of autoimmune CNS inflammation by astrocytes","volume":"37","author":"Rothhammer","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cell.2018.12.012","article-title":"Environmental control of astrocyte pathogenic activities in CNS inflammation","volume":"176","author":"Wheeler","year":"2019","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1523\/JNEUROSCI.1137-14.2014","article-title":"Conditional ablation of astroglial CCL2 suppresses CNS accumulation of M1 macrophages and preserves axons in mice with MOG peptide EAE","volume":"34","author":"Moreno","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jneuroim.2014.06.009","article-title":"Astrocyte CCL2 sustains immune cell infiltration in chronic experimental autoimmune encephalomyelitis","volume":"274","author":"Kim","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/brain\/awh680","article-title":"Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment","volume":"129","author":"Krumbholz","year":"2006","journal-title":"Brain"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/eji.201242679","article-title":"Astrocytic Fas ligand expression is required to induce T-cell apoptosis and recovery from experimental autoimmune encephalomyelitis","volume":"43","author":"Wang","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12964-023-01324-9","article-title":"Natural killer cells in the central nervous system","volume":"21","author":"Ning","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jaut.2016.04.003","article-title":"Dysregulation of regulatory CD56bright NK cells\/T cells interactions in multiple sclerosis","volume":"72","author":"Laroni","year":"2016","journal-title":"J. Autoimmun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"781","DOI":"10.4049\/jimmunol.1100789","article-title":"Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis","volume":"187","author":"Jiang","year":"2011","journal-title":"J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Nielsen, N., \u00d8dum, N., Urs\u00f8, B., Lanier, L.L., and Spee, P. (2012). Cytotoxicity of CD56bright NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94\/NKG2A. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0031959"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"E2973","DOI":"10.1073\/pnas.1524924113","article-title":"Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation","volume":"113","author":"Gross","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e73849","DOI":"10.7554\/eLife.73849","article-title":"Single-cell profiling reveals periventricular CD56bright NK cell accumulation in multiple sclerosis","volume":"11","author":"Kamermans","year":"2022","journal-title":"elife"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1002\/eji.200526122","article-title":"Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood","volume":"35","author":"Bratke","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"a034470","DOI":"10.1101\/cshperspect.a034470","article-title":"Daclizumab therapy for multiple sclerosis","volume":"9","author":"Bielekova","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1073\/pnas.0601335103","article-title":"Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R\u03b1-targeted therapy (daclizumab) in multiple sclerosis","volume":"103","author":"Bielekova","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41467-020-20594-2","article-title":"A CD8+ NK cell transcriptomic signature associated with clinical outcome in relapsing remitting multiple sclerosis","volume":"12","author":"McKinney","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1096\/fj.05-5465com","article-title":"The neuronal chemokine CX3CL1\/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system","volume":"20","author":"Huang","year":"2006","journal-title":"FASEB J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1084\/jem.20092749","article-title":"Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology","volume":"207","author":"Hao","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-020-03116-4","article-title":"Gut-licensed IFN\u03b3+ NK cells drive LAMP1+TRAIL+ anti-inflammatory astrocytes","volume":"590","author":"Sanmarco","year":"2021","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00401-017-1706-x","article-title":"Differential contribution of immune effector mechanisms to cortical demyelination in multiple sclerosis","volume":"134","author":"Wrzos","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1179069519856876","DOI":"10.1177\/1179069519856876","article-title":"Adult neurogenesis and the promise of adult neural stem cells","volume":"13","author":"Ghosh","year":"2019","journal-title":"J. Exp. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nn.4211","article-title":"Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation","volume":"19","author":"Liu","year":"2016","journal-title":"Nat. Neurosci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/bpa.12546","article-title":"Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis","volume":"28","author":"Loveless","year":"2018","journal-title":"Brain Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1073\/pnas.79.10.3290","article-title":"Complement activation by isolated myelin: Activation of the classical pathway in the absence of myelin-specific antibodies","volume":"79","author":"Vanguri","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2990.1989.tb01231.x","article-title":"Immunocytochemical localization of the terminal complement complex in multiple sclerosis","volume":"15","author":"Compston","year":"1989","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/2051-5960-2-53","article-title":"Complement activation in multiple sclerosis plaques: An immunohistochemical analysis","volume":"2","author":"Ingram","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bbi.2020.03.004","article-title":"Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis","volume":"87","author":"Hammond","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/1352458518760715","article-title":"Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis","volume":"25","author":"Roostaei","year":"2019","journal-title":"Mult. Scler. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/jamaneurol.2017.4842","article-title":"Differences in the responses to apheresis therapy of patients with 3 histopathologically classified immunopathological patterns of multiple sclerosis","volume":"75","author":"Stork","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"577147","DOI":"10.1016\/j.jneuroim.2020.577147","article-title":"Complement activation in cerebrospinal fluid in clinically isolated syndrome and early stages of relapsing remitting multiple sclerosis","volume":"340","author":"Ernerudh","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Mader, S., and Brimberg, L. (2019). Aquaporin-4 water channel in the brain and its implication for health and disease. Cells, 8.","DOI":"10.3390\/cells8020090"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.4049\/jimmunol.181.8.5730","article-title":"Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment","volume":"181","author":"Vincent","year":"2008","journal-title":"J. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20081241","article-title":"Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2","volume":"205","author":"Hinson","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-012-0986-4","article-title":"Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss","volume":"123","author":"Ratelade","year":"2012","journal-title":"Acta Neuropathol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e21856","DOI":"10.1096\/fj.202100673R","article-title":"Group 2 innate lymphoid cells suppress the pathology of neuromyelitis optica spectrum disorder","volume":"35","author":"Kong","year":"2021","journal-title":"FASEB J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/1352458512440060","article-title":"Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein","volume":"18","author":"Herges","year":"2012","journal-title":"Mult. Scler."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ana.22686","article-title":"Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain","volume":"71","author":"Saadoun","year":"2012","journal-title":"Ann. Neurol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: A cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"17406","DOI":"10.1074\/jbc.R113.546218","article-title":"Eosinophil granule proteins: Form and function","volume":"289","author":"Acharya","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: Lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/glia.22635","article-title":"Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures","volume":"62","author":"Howe","year":"2014","journal-title":"Glia"},{"key":"ref_88","first-page":"4025","article-title":"Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.neuron.2018.10.014","article-title":"Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies","volume":"100","author":"Dejanovic","year":"2018","journal-title":"Neuron"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1523\/JNEUROSCI.5249-09.2010","article-title":"Complement component C1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury","volume":"30","author":"Ten","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_91","first-page":"325","article-title":"The roles of microglia and astrocytes in myelin phagocytosis in the central nervous system","volume":"42","author":"Xu","year":"2022","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fncel.2018.00178","article-title":"mCSF-induced microglial activation prevents myelin loss and promotes its repair in a mouse model of multiple sclerosis","volume":"12","author":"Laflamme","year":"2018","journal-title":"Front Cell Neurosci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12974-023-02772-3","article-title":"TREM2 deficiency inhibits microglial activation and aggravates demyelinating injury in neuromyelitis optica spectrum disorder","volume":"20","author":"You","year":"2023","journal-title":"J. Neuroinflamm."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0165-5728(89)90014-3","article-title":"Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturation","volume":"22","author":"Scolding","year":"1989","journal-title":"J. Neuroimmunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"101944","DOI":"10.1016\/j.smim.2025.101944","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis","volume":"78","author":"Andersen","year":"2025","journal-title":"Semin. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Kohyama, K., Nishida, H., Kaneko, K., Misu, T., Nakashima, I., and Sakuma, H. (2023). Complement-dependent cytotoxicity of human autoantibodies against myelin oligodendrocyte glycoprotein. Front. Neurosci., 17.","DOI":"10.3389\/fnins.2023.1014071"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"Guo","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: An immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"key":"ref_99","first-page":"e165373","article-title":"MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity","volume":"8","author":"Yandamuri","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ana.26226","article-title":"Complement activation is a prominent feature of MOGAD","volume":"90","author":"Keller","year":"2021","journal-title":"Ann. Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/brain\/awab105","article-title":"Features of MOG required for recognition by patients with MOG antibody-associated disorders","volume":"144","author":"Macrini","year":"2021","journal-title":"Brain"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: An update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1375\/twin.14.2.129","article-title":"Utilizing twins concordance rates to infer the predisposition to myasthenia gravis","volume":"14","author":"Ramanujam","year":"2011","journal-title":"Twin Res. Hum. Genet."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.4049\/jimmunol.167.4.1935","article-title":"Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis","volume":"167","author":"Sims","year":"2001","journal-title":"J. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.autrev.2018.10.005","article-title":"Innate immune responses and their role in driving autoimmunity","volume":"18","author":"Toubi","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"102382","DOI":"10.1016\/j.jaut.2019.102382","article-title":"Innate immunity as the trigger of systemic autoimmune diseases","volume":"110","author":"Saferding","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"102800","DOI":"10.1016\/j.autrev.2021.102800","article-title":"The role of innate immunity in myasthenia gravis","volume":"20","author":"Zhao","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1212\/WNL.0b013e3181d7d884","article-title":"Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis","volume":"74","author":"Cavalcante","year":"2010","journal-title":"Neurology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0002-9440(10)62960-4","article-title":"Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution","volume":"167","author":"Bernasconi","year":"2005","journal-title":"Am. J. Pathol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ana.21902","article-title":"Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus","volume":"67","author":"Cavalcante","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"95432","DOI":"10.18632\/oncotarget.20731","article-title":"Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: An innocent bystander or an autoimmunity mediator?","volume":"8","author":"Cavalcante","year":"2017","journal-title":"Oncotarget"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ana.23791","article-title":"Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis","volume":"73","author":"Cufi","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ana.21628","article-title":"CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia","volume":"66","author":"Ruhlmann","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jaut.2013.12.016","article-title":"Central role of interferon-beta in thymic events leading to myasthenia gravis","volume":"52","author":"Cufi","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: The role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.autrev.2017.11.018","article-title":"NK cells in autoimmune diseases: Linking innate and adaptive immune responses","volume":"17","author":"Gianchecchi","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.192.11.1553","article-title":"CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function","volume":"192","author":"Schaerli","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-019-1687-x","article-title":"CXCR5-negative natural killer cells ameliorate experimental autoimmune myasthenia gravis by suppressing follicular helper T cells","volume":"16","author":"Yang","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/j.1468-1331.2011.03424.x","article-title":"Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis","volume":"18","author":"Chien","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: From molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.4049\/jimmunol.175.12.7898","article-title":"Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia","volume":"175","author":"Liu","year":"2005","journal-title":"J. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12974-015-0334-4","article-title":"Caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate dendritic cell IL-1\u2013IL-17 pathway","volume":"12","author":"Wang","year":"2015","journal-title":"J. Neuroinflamm."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","article-title":"Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"268","author":"Querol","year":"2021","journal-title":"J. Neurol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s13311-022-01221-y","article-title":"The role of the complement system in chronic inflammatory demyelinating polyneuropathy: Implications for complement-targeted therapies","volume":"19","author":"Querol","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0165-5728(88)90101-4","article-title":"Immune reactive C3d on the surface of myelin sheaths in neuropathy","volume":"18","author":"Hays","year":"1988","journal-title":"J. Neuroimmunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archneur.1980.00500590061010","article-title":"Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy","volume":"37","author":"Dalakas","year":"1980","journal-title":"Arch. Neurol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/acn3.331","article-title":"Terminal complement activation is increased and associated with disease severity in CIDP","volume":"3","author":"Quast","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s004010050801","article-title":"Systemic complement depletion reduces inflammation and demyelination in adoptive transfer experimental allergic neuritis","volume":"95","author":"Vriesendorp","year":"1998","journal-title":"Acta Neuropathol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0006-8993(87)90572-5","article-title":"Complement depletion suppresses Lewis rat experimental allergic neuritis","volume":"419","author":"Feasby","year":"1987","journal-title":"Brain Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0304-3940(95)12115-K","article-title":"Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats","volume":"200","author":"Jung","year":"1995","journal-title":"Neurosci. Lett."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2012-07-441857","article-title":"CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy","volume":"121","author":"Nevo","year":"2013","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2200030","DOI":"10.1002\/adtp.202200030","article-title":"Classical complement pathway inhibition in a \u201chuman-on-a-Chip\u201d model of autoimmune demyelinating neuropathies","volume":"5","author":"Rumsey","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/ana.410270717","article-title":"Macrophage responses in inflammatory demyelinating neuropathies","volume":"27","author":"Griffin","year":"1990","journal-title":"Ann. Neurol."},{"key":"ref_134","first-page":"133","article-title":"Acute idiopathic polyneuritis: An electron microscope study","volume":"26","author":"Prineas","year":"1972","journal-title":"Lab. Investig."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1212\/WNL.58.6.979","article-title":"Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS","volume":"58","author":"Mori","year":"2002","journal-title":"Neurology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0301-0082(00)00060-5","article-title":"The role of macrophages in immune-mediated damage to the peripheral nervous system","volume":"64","author":"Kiefer","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1212\/WNL.44.6.1153","article-title":"Serum levels of soluble E-selectin (ELAM-1) in immune-mediated neuropathies","volume":"44","author":"Hartung","year":"1994","journal-title":"Neurology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/135245859800400110","article-title":"Soluble intercellular adhesion molecule-I (sICAM-I) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system","volume":"4","author":"Trojano","year":"1998","journal-title":"Mult. Scler."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.53.1.62","article-title":"Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy","volume":"53","author":"Leppert","year":"1999","journal-title":"Neurology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0923-2494(92)80040-R","article-title":"Nerve lesions induced by macrophage activation","volume":"143","author":"Said","year":"1992","journal-title":"Res. Immunol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ana.410400414","article-title":"Acute motor axonal neuropathy: An antibody-mediated attack on axolemma","volume":"40","author":"Hsieh","year":"1996","journal-title":"Ann. Neurol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1158\/0008-5472.CAN-15-1330","article-title":"Antibody-dependent phagocytosis of tumor cells by macrophages: A potent effector mechanism of monoclonal antibody therapy of cancer","volume":"75","author":"Gul","year":"2015","journal-title":"Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e00516","DOI":"10.1002\/brb3.516","article-title":"Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"6","author":"Dyer","year":"2016","journal-title":"Brain Behav."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e884","DOI":"10.1212\/NXI.0000000000000884","article-title":"NK cell markers predict the efficacy of IV immunoglobulins in CIDP","volume":"7","author":"Mausberg","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: A review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/ern.13.17","article-title":"Treating multiple sclerosis with monoclonal antibodies: A 2013 update","volume":"13","author":"Deiss","year":"2013","journal-title":"Expert Rev. Neurother."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1212\/NXI.0000000000000117","article-title":"Randomized phase 1b trial of mor103, a human antibody to GM-CSF, in multiple sclerosis","volume":"2","author":"Constantinescu","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Chen, S., Zhou, J., Cai, Y., Zheng, X., Xie, S., Liao, Y., Zhu, Y., Qin, C., Lai, W., and Yang, C. (2017). Discovery of BVDU as a promising drug for autoimmune diseases therapy by dendritic-cell-based functional screening. Sci. Rep., 7.","DOI":"10.1038\/srep43820"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.immuni.2004.05.002","article-title":"Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo","volume":"20","author":"Hawiger","year":"2004","journal-title":"Immunity"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.immuni.2016.10.008","article-title":"Immunomodulatory functions of BTLA and HVEM govern induction of extrathymic regulatory T cells and tolerance by dendritic cells","volume":"45","author":"Jones","year":"2016","journal-title":"Immunity"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.4049\/jimmunol.180.6.3647","article-title":"Cutting edge: Langerin\/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo","volume":"180","author":"Idoyaga","year":"2008","journal-title":"J. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4049\/jimmunol.1102541","article-title":"Treml4, an Ig superfamily member, mediates presentation of several antigens to T cells in vivo, including protective immunity to HER2 protein","volume":"188","author":"Hemmi","year":"2012","journal-title":"J. Immunol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/eji.201040419","article-title":"Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1\/Clec9A","volume":"40","author":"Joffre","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1126\/science.1136080","article-title":"Differential antigen processing by dendritic cell subsets in vivo","volume":"315","author":"Dudziak","year":"2007","journal-title":"Science"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.4049\/jimmunol.1102307","article-title":"Antigen targeting to plasmacytoid dendritic cells via Siglec-H inhibits Th cell-dependent autoimmunity","volume":"187","author":"Loschko","year":"2011","journal-title":"J. Immunol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.4049\/jimmunol.1004029","article-title":"Antigen delivery to plasmacytoid dendritic cells via BST2 induces protective T cell-mediated immunity","volume":"186","author":"Loschko","year":"2011","journal-title":"J. Immunol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/eji.201242402","article-title":"Fulfilling the dream: Tolerogenic dendritic cells to treat multiple sclerosis","volume":"42","author":"Gross","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3349\/ymj.2018.59.7.807","article-title":"Generation, characteristics and clinical trials of ex vivo generated tolerogenic dendritic cells","volume":"59","author":"Kim","year":"2018","journal-title":"Yonsei Med. J."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.it.2015.05.007","article-title":"Harnessing nanoparticles for immune modulation","volume":"36","author":"Getts","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"eaaf8665","DOI":"10.1126\/sciimmunol.aaf8665","article-title":"Arc\/Arg3.1 governs inflammatory dendritic cell migration from the skin and thereby controls T cell activation","volume":"1","author":"Ufer","year":"2016","journal-title":"Sci. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.expneurol.2018.05.021","article-title":"Csf1R inhibition attenuates experimental autoimmune encephalomyelitis and promotes recovery","volume":"307","author":"Nissen","year":"2018","journal-title":"Exp. Neurol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.clim.2018.02.012","article-title":"A novel PADRE-Kv1.3 vaccine effectively induces therapeutic antibodies and ameliorates experimental autoimmune encephalomyelitis in rats","volume":"193","author":"Fan","year":"2018","journal-title":"Clin. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u2014Revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management","volume":"271","author":"Giglhuber","year":"2024","journal-title":"J. Neurol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ncl.2023.06.009","article-title":"Updates in NMOSD and MOGAD diagnosis and treatment: A tale of two central nervous system autoimmune inflammatory disorders","volume":"42","author":"Cacciaguerra","year":"2024","journal-title":"Neurol. Clin."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann. Neurol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/13524585211038291","article-title":"Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension","volume":"28","author":"Pittock","year":"2022","journal-title":"Mult. Scler."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"102641","DOI":"10.1016\/j.msard.2020.102641","article-title":"Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial","volume":"47","author":"Palace","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1212\/NXI.0000000000000441","article-title":"Open-label, add-on trial of cetirizine for neuromyelitis optica","volume":"5","author":"Fabian","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"103693","DOI":"10.1016\/j.autrev.2024.103693","article-title":"MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","volume":"24","author":"Trewin","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1756285617749134","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: Clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1136\/ard.2004.033753","article-title":"Type I interferon correlates with serological and clinical manifestations of SLE","volume":"64","author":"Cardarelli","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/13543776.2016.1185415","article-title":"Recent progress in the development of Toll-like receptor (TLR) antagonists","volume":"26","author":"Patra","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_177","first-page":"A95","article-title":"A phase I, first-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of M5049, a dual antagonist of TLR7\/8, in healthy subjects","volume":"7","author":"Port","year":"2020","journal-title":"Lupus Sci. Med."},{"key":"ref_178","first-page":"A28","article-title":"M5049, a novel potent and selective inhibitor of toll-like receptors 7 and 8 (TLR7\/8)","volume":"7","author":"Sherer","year":"2020","journal-title":"Lupus Sci. Med."},{"key":"ref_179","first-page":"S26","article-title":"IMO-3100, an antagonist of toll-like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients with 4 weeks of treatment in a phase 2a trial","volume":"133","author":"Kimball","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","article-title":"\u2018Minimal symptom expression\u2019 in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume":"267","author":"Vissing","year":"2020","journal-title":"J. Neurol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","article-title":"A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients","volume":"271","author":"Pane","year":"2024","journal-title":"J. Neurol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s10072-023-07190-0","article-title":"Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors","volume":"45","author":"Fionda","year":"2024","journal-title":"Neurol. Sci."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: Results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Sheridan, D., Yu, Z.-X., Zhang, Y., Patel, R., Sun, F., Lasaro, M.A., Bouchard, K., Andrien, B., Marozsan, A., and Wang, Y. (2018). Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195909"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e70158","DOI":"10.1111\/ene.70158","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: Final results from the phase 3 CHAMPION MG open-label extension","volume":"32","author":"Vu","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1716995","article-title":"Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema","volume":"379","author":"Bygum","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","article-title":"Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor","volume":"376","author":"Longhurst","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1097\/TP.0000000000002717","article-title":"Update on C1 esterase inhibitor in human solid organ transplantation","volume":"103","author":"Berger","year":"2019","journal-title":"Transplantation"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): A randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/jns.12573","article-title":"Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial","volume":"28","author":"Bril","year":"2023","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: A double-blind, sham-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410110205","article-title":"Prednisone improves chronic inflammatory demyelinating polyneuropathy more than no treatment","volume":"11","author":"Dyck","year":"1982","journal-title":"Ann. Neurol."},{"key":"ref_196","first-page":"1361","article-title":"Efficacy of azathioprine and methotrexate in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"36","author":"Mehreen","year":"2023","journal-title":"Pak. J. Pharm. Sci."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4155\/tde-2023-0085","article-title":"Argenx reports positive topline data from ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy","volume":"14","author":"Timmins","year":"2023","journal-title":"Ther. Deliv."},{"key":"ref_198","unstructured":"(2025, February 09). A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (MyCIDPchoice), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/results\/NCT03861481."},{"key":"ref_199","unstructured":"(2025, February 09). Efficacy and Safety Study of Nipocalimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05327114."},{"key":"ref_200","unstructured":"(2025, February 09). To Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05581199."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1212\/NXI.0000000000000720","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy","volume":"7","author":"Castellani","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3988\/jcn.2023.0127","article-title":"Therapeutic outcomes and electrophysiological biomarkers in anti-myelin-associated glycoprotein neuropathy: A multicenter cohort study in South Korea","volume":"20","author":"Min","year":"2024","journal-title":"J. Clin. Neurol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/cts.13481","article-title":"First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor","volume":"16","author":"Chow","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/jns.12551","article-title":"An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy","volume":"28","author":"Querol","year":"2023","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/13543784.2024.2394186","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: Results from a Phase 1, randomized, open-label trial","volume":"33","author":"Li","year":"2024","journal-title":"Expert Opin. Investig. Drugs"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/20\/7235\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:22:02Z","timestamp":1760530922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/20\/7235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":205,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jcm14207235"],"URL":"https:\/\/doi.org\/10.3390\/jcm14207235","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]}}}